Edge Therapeutics (NASDAQ: EDGE) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare Edge Therapeutics to similar companies based on the strength of its risk, analyst recommendations, institutional ownership, dividends, earnings, profitability and valuation.

Valuation and Earnings

This table compares Edge Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Edge Therapeutics N/A -$38.82 million -6.01
Edge Therapeutics Competitors $284.49 million $34.10 million 70.05

Edge Therapeutics’ rivals have higher revenue and earnings than Edge Therapeutics. Edge Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Edge Therapeutics and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Edge Therapeutics 0 1 1 0 2.50
Edge Therapeutics Competitors 893 3287 11783 235 2.70

Edge Therapeutics currently has a consensus price target of $25.50, suggesting a potential upside of 172.15%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.13%. Given Edge Therapeutics’ higher probable upside, analysts plainly believe Edge Therapeutics is more favorable than its rivals.

Profitability

This table compares Edge Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Edge Therapeutics N/A -56.88% -43.74%
Edge Therapeutics Competitors -5,145.19% -170.27% -35.98%

Insider and Institutional Ownership

50.3% of Edge Therapeutics shares are owned by institutional investors. Comparatively, 49.7% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 36.2% of Edge Therapeutics shares are owned by company insiders. Comparatively, 17.5% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk and Volatility

Edge Therapeutics has a beta of 2.52, suggesting that its share price is 152% more volatile than the S&P 500. Comparatively, Edge Therapeutics’ rivals have a beta of 5.98, suggesting that their average share price is 498% more volatile than the S&P 500.

Summary

Edge Therapeutics rivals beat Edge Therapeutics on 7 of the 12 factors compared.

Edge Therapeutics Company Profile

Edge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions. The Company’s product candidates utilize its programmable, biodegradable polymer-based development platform (the Precisa Platform), a delivery mechanism that seeks to enable targeted and sustained drug exposure and avoid the dose-limiting side effects associated with the current standards of care. The Company’s product candidates include EG-1962 and EG-1964. EG-1962 is a polymer-based microsphere containing nimodipine suspended in a diluent of sodium hyaluronate was developed using its Precisa development platform to improve patient outcomes following aneurysmal subarachnoid hemorrhage (aSAH).

Receive News & Ratings for Edge Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.